Kognitive Dysfunktion im Rahmen einer Krebserkrankung und ihrer Behandlung

Summary

Die kognitive Dysfunktion hat sich heute zu einer der am häufigsten auftretenden und die Krebspatient*innen oft langfristig am meisten beeinträchtigenden Begleiterscheinungen ihrer Erkrankung entwickelt. Mit den im Rahmen der konventionellen Therapie zur Verfügung stehenden Maßnahmen, insbesondere kognitivem Training, Psychoedukation und körperlicher Aktivität, ergibt sich für viele Patient*innen keine ausreichend zufriedenstellende Besserung. Vor diesem Hintergrund und weil ein großer Anteil der Patient*innen grundsätzlich eine integrative Behandlung ihrer Beschwerden wünscht, werden sehr häufig auch komplementärmedizinische Therapieansätze erfragt.

In dieser Zusammenstellung soll ein Überblick über bereits in ersten klinischen Studien wissenschaftlich untersuchte Therapieverfahren, aber auch über vielversprechende weitere Therapieansätze gegeben werden.

Keywords

Krebs - Krebstherapie - Onkologie - Kognitive Dysfunktion - Phytopharmaka

Publication History

Article published online:
12 December 2023

• Literatur

• 1 Wefel JS, Kesler SR, Noll KR. et al Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 2015; 65 (02) 123-138 DOI: 10.3322/caac.21258.
• 2 Fernandes HA, Richard NM, Edelstein K. Cognitive rehabilitation for cancer-related cognitive dysfunction: A systematic review. Support Care Cancer 2019; 27 (09) 3253-3279 DOI: 10.1007/s00520-019-04866-2.
• 3 Hardy SJ, Krull KR, Wefel JS. et al Cognitive changes in cancer survivors. Am Soc Clin Oncol Educ Book 2018; 38: 795-806 DOI: 10.1200/EDBK_201179.
• 4 Cerulla Torrente N, Navarro Pastor JB, de la Osa Chaparro N. Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy. J Cancer Surviv 2020; 14 (04) 464-482 DOI: 10.1007/s11764-020-00870-2.
• 5 Lange M, Joly F, Vardy J. et al Cancer-related cognitive impairment: An update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol 2019; 30 (12) 1925-1940 DOI: 10.1093/annonc/mdz410.
• 6 Yang M, Kim J, Kim JS. et al Hippocampal dysfunctions in tumor-bearing mice. Brain Behav Immun 2014; 36: 147-155 DOI: 10.1016/j.bbi.2013.10.022.
• 7 Dietrich J, Han R, Yang Y. et al CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006; 05 (07) 22 DOI: 10.1186/jbiol50.
• 8 Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 2012; 12 (03) 267-275 DOI: 10.1007/s11910-012-0264-9.
• 9 Briones TL, Woods J. Dysregulation in myelination mediated by persistent neuroinflammation: Possible mechanisms in chemotherapy-related cognitive impairment. Brain Behav Immun 2014; 35: 23-32
• 10 Wefel JS, Ryan CJ, Van J. et al Assessment and management of cognitive function in patients with prostate cancer treated with second-generation androgen receptor pathway inihibitors. CNS Drugs 36 (05) 419-449 DOI: 10.1007/s40263-022-00913-5.
• 11 Zwart W, Terra H, Linn SC. et al Cognitive effects of endocrine therapy for breast cancer: Keep calm and carry on?. Nat Rev Clin Oncol 2015; 12 (10) 597-606 DOI: 10.1038/nrclinonc.2015.124.
• 12 Hermelink K, Bühner M, Sckopke P. et al Chemotherapy and post-traumatic stress in the causation of cognitive dysfunction in breast cancer patients. J Natl Cancer Inst 2017; 109: 10 DOI: 10.1093/jnci/djx057..
• 13 Schilling G. Das sogenannte „Chemobrain“ – Kognitive Dysfunktion bei Krebskranken – ein oft unterbewertetes Symptom. Im Fokus Onkologie 2023; 26 (04) 52-56
• 14 Deutsche Krebshilfe, Deutsche Krebsgesellschaft AWMF. S3-Leitlinie Komplementärmedizin in der Behandlung von onkologischen PatientInnen (09/2021). Im Internet. www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin Stand: 06.11.2023
• 15 Derry HM, Jaremka LM, Bennett JM. et al Yoga and self-reported cognitive problems in breast cancer survivors: A randomized controlled trial. Psychooncology 2015; 24 (08) 958-966 DOI: 10.1002/pon.3707.
• 16 Janelsins MC, Peppone LJ, Heckler CE. et al YOCAS©® yoga reduces self-reported memory difficulty in cancer survivors in a nationwide randomized clinical trial: Investigating relationships between memory and sleep. Integr Cancer Ther 2016; 15 (03) 263-271 DOI: 10.1177/1534735415617021.
• 17 Cramer H, Lauche R, Klose P. et al Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev 2017; 01 (01) CD010802 DOI: 10.1002/14651858.CD010802.pub2.
• 18 Johns SA, Brown LF, Beck-Coon K. et al Randomized controlled pilot trial of mindfulness-based stress reduction compared to psychoeducational support for persistently fatigued breast and colorectal cancer survivors. Support Care Cancer 2016; 24 (10) 4085-4096 DOI: 10.1007/s00520-016-3220-4.
• 19 Tong T, Pei C, Chen J. et al Efficacy of acupuncture therapy for chemotherapy-related cognitive impairment in breast cancer patients. Med Sci Monit 2018; 24: 2919-2927 DOI: 10.12659/MSM.909712.
• 20 Seo EJ, Klauck SM, Efferth T. et al Adaptogens in chemobrain (Part I): Plant extracts attenuate cancer chemotherapy-induced cognitive impairment – Transcriptome-wide microarray profiles of neuroglia cells. Phytomedicine 2019; 55: 80-91 DOI: 10.1016/j.phymed.2018.10.022.21.
• 21 Abulizi A, Ran J, Ye Y. et al Ganoderic acid improves 5-fluorouracil-induced cognitive dysfunction in mice. Food Funct 2021; 12 (24) 12325-12337 DOI: 10.1039/D1FO03055H.
• 22 Sadeghian M, Rahmani S, Zendehdel M. et al Ginseng and cancer-related fatigue: A systematic review of clinical trials. Nutr Cancer 2021; 73 (08) 1270-1281 DOI: 10.1080/01635581.2020.1795691.
• 23 Darbinyan V, Aslanyan G, Amroyan E et a. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry 2007; 61 (05) 343-348 DOI: 10.1080/08039480701643290.
• 24 Ishaque S, Shamseer L, Bukutu C. et al Rhodiola rosea for physical and mental fatigue: A systematic review. BMC Complement Altern Med 2012; 12: 70 DOI: 10.1186/1472-6882-12-70.
• 25 Barton DL, Atherton PJ, Bauer BA. et al The use of valeriana officinalis (valerian) in improving sleep in patients who are undergoing treatment for cancer: A phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J Support Oncol 2011; 09 (01) 24-31 DOI: 10.1016/j.suponc.2010.12.008.
• 26 Zick SM, Sen A, Wyatt GK. et al Investigation of 2 types of self-administered acupressure for persistent cancer-related fatigue in breast cancer survivors: A randomized clinical trial. JAMA Oncol 2016; 02 (11) 1470-1476 DOI: 10.1001/jamaoncol.2016.1867.
• 27 Speers AB, Cabey KA, Soumyanath A. et al Effects of withania somnifera (ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia. Curr Neuropharmacol 2021; 19 (09) 1468-1495 DOI: 10.2174/1570159X19666210712151556.
• 28 Biswal BM, Sulaiman SA, Ismail HC. et al Effect of withania somnifera (ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther 2013; 12 (04) 312-322 DOI: 10.1177/1534735412464551.
• 29 Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008; 2008 (04) CD000448 DOI: 10.1002/14651858.CD000448.pub3.
• 30 European Medicines Agency. European Union herbal monograph on Ginkgo biloba L., folium EMA/HMPC/2012; (28.01.2015). Im Internet. https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-ginkgo-biloba-l-folium_en.pdf Stand: 06.11.2023
• 31 Attia A, Rapp SR, Case LD. et al Phase II study of Ginkgo biloba in irradiated brain tumor patients: Effect on cognitive function, quality of life, and mood. J Neurooncol 2012; 109 (02) 357-363 DOI: 10.1007/s11060-012-0901-9.
• 32 Barton DL, Burger K, Novotny PJ. et al The use of ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 2013; 21 (04) 1185-1192 DOI: 10.1007/s00520-012-1647-9.
• 33 Pelzer F, Loef M, Martin DD. et al Cancer-related fatigue in patients treated with mistletoe extracts: A systematic review and meta-analysis. Support Care Cancer 2022; 30 (08) 6405-6418 DOI: 10.1007/s00520-022-06921-x.
• 34 Dominguez LJ, Barbagallo M. Nutritional prevention of cognitive decline and dementia. Acta Biomed 2018; 89 (02) 276-290 DOI: 10.23750/abm.v89i2.7401.
• 35 Fried TR, Bradley EH, Towle VR. et al Understanding the treatment preferences of seriously ill patients. N Engl J Med 2002; 346 (14) 1061-1066 DOI: 10.1056/NEJMsa012528.